Original Article
Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
N Engl J Med 2009; 360:573-587February 5, 2009
- Abstract
Background
Following the release of the 2002 report of the Women's Health Initiative (WHI) trial of estrogen plus progestin, the use of menopausal hormone therapy in the United States decreased substantially. Subsequently, the incidence of breast cancer also dropped, suggesting a cause-and-effect relation between hormone treatment and breast cancer. However, the cause of this decrease remains controversial.
Methods
We analyzed the results of the WHI randomized clinical trial — in which one study group received 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate daily and another group received placebo — and examined temporal trends in breast-cancer diagnoses in the WHI observational-study cohort. Risk factors for breast cancer, frequency of mammography, and time-specific incidence of breast cancer were assessed in relation to combined hormone use.
Results
In the clinical trial, there were fewer breast-cancer diagnoses in the group receiving estrogen plus progestin than in the placebo group in the initial 2 years of the study, but the number of diagnoses increased over the course of the 5.6-year intervention period. The elevated risk decreased rapidly after both groups stopped taking the study pills, despite a similar frequency of mammography. In the observational study, the incidence of breast cancer was initially about two times as high in the group receiving menopausal hormones as in the placebo group, but this difference in incidence decreased rapidly in about 2 years, coinciding with year-to-year reductions in combined hormone use. During this period, differences in the frequency of mammography between the two groups were unchanged.
Conclusions
The increased risk of breast cancer associated with the use of estrogen plus progestin declined markedly soon after discontinuation of combined hormone therapy and was unrelated to changes in frequency of mammography.
Media in This Article
Figure 1
Effects over Time of Estrogen plus Progestin on the Incidence of Breast Cancer in the WHI Clinical Trial.Figure 2
Effects over Time of Estrogen plus Progestin on the Risk of Breast Cancer in the WHI Observational Study.Article Activity
- Article
The Women's Health Initiative (WHI) trial of conjugated equine estrogens plus medroxyprogesterone acetate was stopped when health risks were shown to exceed the benefits of combined hormone therapy.1 The incidence of breast cancer was higher in the hormone-therapy group, and the cancers were larger and more advanced2; in addition, the frequency of abnormalities on mammograms and of breast biopsies was increased in the hormone-therapy group.3
After the release of our initial WHI report, in 2002,1 menopausal hormone use decreased considerably in the United States.4,5 Approximately a year later, a substantial drop in the incidence of breast cancer was observed.6,7 Although several countries subsequently reported similar decreases,8-10 others did not,11,12 and the cause of the decline remains controversial.13,14 The temporal relation between decreased use of menopausal hormones and the drop in the incidence of breast cancer suggested causality, although changes in the frequency of mammographic screening as well as other factors were recognized as possible contributors.6,7 When the WHI trial was stopped, more breast cancers were seen in the follow-up period (mean, 2.4 years) among women who had received estrogen plus progestin than in the placebo group,15 and it appeared that hormone therapy hindered the detection of breast cancer.2,3
Methods
Details of the WHI study have been described elsewhere.16-18 Briefly, postmenopausal women between the ages of 50 and 79 years with an anticipated survival of at least 3 years were eligible. Additional criteria for eligibility were the absence of a history of invasive breast cancer or hysterectomy and a baseline mammogram and clinical breast examination with no suggestion of breast cancer. Women using menopausal hormone therapy were eligible after a 3-month washout period. Subjects were randomly assigned to receive a daily dose of conjugated equine estrogens (0.625 mg) plus medroxyprogesterone acetate (2.5 mg) (Prempro, Wyeth-Ayerst Pharmaceuticals) or an identical-appearing placebo. Randomization was performed by the WHI Clinical Coordinating Center. Study pills were distributed at clinical centers, with the use of a bar-code system to ensure that both staff and participants were unaware of the group assignments. The initial study population consisted of 16,608 women, with the first randomization on October 29, 1993; postintervention follow-up data were available for 15,387 women, none of whom had received a diagnosis of breast cancer, and these women were therefore included in the postintervention analyses.
We also analyzed data collected for 41,449 women enrolled in another WHI investigation, an observational study with eligibility criteria similar to those of the clinical trial: no history of a hysterectomy or breast cancer and normal findings on a mammogram obtained within 2 years before study enrollment; 25,328 of the participants reported no use of menopausal hormone therapy and 16,121 reported use of estrogen plus progestin at baseline. The first enrollment occurred on September 19, 1994, and data were included through December 31, 2005. These women received no instruction from the WHI regarding menopausal hormone use but were sent a letter outlining the results of the estrogen-plus-progestin trial several weeks after the initial publication of the study findings.
All women in both studies gave written informed consent, and the protocols were approved by the institutional review board at each institution.
Data Collection
All participants in both studies provided information on demographic characteristics, risk factors for breast cancer, medical and family histories, and lifestyle using standardized self-reporting instruments. Information on past use of hormones was obtained by trained interviewers using structured questionnaires. Ongoing use of hormone therapy in the observational study was determined annually by means of questionnaires. Mammography was performed at WHI clinical centers and at community sites,19 and the reports were coded in accordance with radiologists' recommendations. Mammographic findings were considered to be abnormal if a physician-directed intervention was recommended (either follow-up after a short interval or further evaluation because of a finding that was suspicious or highly suggestive of cancer).
Follow-up and Termination Procedures
Clinical outcomes were reported in a self-administered questionnaire at 6-month intervals for the clinical trial and annually for the observational study. Breast cancers were confirmed by a review of pathology reports performed by local physician adjudicators, followed by adjudication at the Clinical Coordinating Center.3 In the clinical trial, mammograms and breast examinations were required annually, and the administration of study pills was continued only after adherence to the regimen during the previous year had been documented. In the observational study, mammography use was not defined by the protocol. Decisions regarding diagnostic procedures for breast cancer were made by community physicians. Recommendations to perform breast biopsies were based on clinical findings.
The intervention phase of the trial was terminated when an excessive net risk of combined hormone therapy was identified.1 All participants were instructed to stop taking the study pills (active or placebo) immediately, in a letter that was intended for receipt on the day before the trial results were published (July 8, 2002). This letter initiated the postintervention phase of the trial. The originally specified date of trial completion (March 31, 2005) was the end date for the current analyses. During the postintervention phase, participants were followed on the same schedule and were encouraged to continue having annual mammograms. Information on the frequency of mammography and on clinical outcomes was collected for the observational study during a similar time period.
Statistical Analysis
Baseline characteristics of participants in the clinical trial were compared with the use of the chi-square test, Fisher's exact test, or Student's t-test. Hazard ratios for the intervention and postintervention phases of the trial were estimated from Cox proportional-hazards analysis, stratified according to age and randomized assignment in the dietary-modification trial, a concurrent WHI clinical trial that participants could also enter.15 Additional analyses of the influence of menopausal hormones on the risk of invasive breast cancer depict linear, time-varying hazard ratios over the period of the intervention and postintervention phases. To determine whether temporal trends differed between the two phases, the equality of the slopes between the two linear estimates was tested. To confirm that the linear fits were reasonable, hazard ratios for the hormone-therapy and placebo groups were determined for sequential 6-month intervals and were visually compared with the linear hazard-ratio estimates. Sensitivity analyses for adherence were conducted after censoring of data for events that occurred 6 months after a woman became nonadherent (i.e., was using <80% of study pills). Time-varying weights, inversely proportional to the estimated probability of continued adherence, were used in the proportional-hazards models to maintain the distribution of the sample characteristics during follow-up.
In the observational study, the comparison of women who used estrogen plus progestin with nonusers, defined at enrollment, was based on calendar time. Since the study did not direct participants to stop using hormone therapy, we fitted a smooth, nonparametric hazard-ratio estimate for the influence of combined hormone therapy on the risk of breast cancer,20 with the results expressed as a test for trend with one degree of freedom. To confirm that the smoothed fit was reasonable, hazard ratios were calculated for sequential 6-month intervals and visually compared with the smoothed estimate. Both parametric and nonparametric regression models were adjusted for age, race or ethnic group, body-mass index, education, smoking status, use or nonuse of alcohol, health status, level of physical activity, presence or absence of a family history of breast cancer, estimated breast-cancer risk based on the Gail model,21 and bilateral oophorectomy and were stratified according to age.
We also performed sensitivity analyses for adherence in the observational study, censoring data for participants who changed their status with respect to estrogen-plus-progestin use from that reported at entry, before July 8, 2002, and comparing the incidence of breast cancer among the women who were regularly using hormones at entry with the incidence among those who were not. Linear, time-varying hazard ratios were calculated, with the use of the same regression-model adjustments as those listed above, for the intervention and postintervention periods, and the equality of slopes between the two linear estimates was tested. Time-varying weights, inversely proportional to the estimated probability of no change in status with regard to the use of estrogen plus progestin, were used to maintain the distribution of the sample characteristics during follow-up. SAS software, version 9.1.3 (SAS Institute), was used.
Results
Clinical Trial
For the 15,387 participants in the clinical trial who had not previously received a diagnosis of invasive breast cancer and for whom any follow-up data during the postintervention phase were available, risk factors for breast cancer were balanced between the two randomized study groups (Table 1Table 1
Characteristics of the Participants in the Postintervention Phase of the Clinical Trial.) (P>0.10 for all tests of association). As previously reported, the risk of invasive breast cancer was higher in the hormone-therapy group than in the placebo group during the intervention phase (199 cases vs. 150 cases; hazard ratio, 1.26; 95% confidence interval [CI], 1.02 to 1.55).2 The linear, time-varying hazard ratios used to calculate the influence of menopausal hormones on the risk of breast cancer were below 1.00 (but were not significantly different from 1.00) during the first 2 years of the trial, subsequently increased throughout the intervention phase, and decreased during postintervention (Figure 1Figure 1Effects over Time of Estrogen plus Progestin on the Incidence of Breast Cancer in the WHI Clinical Trial.). In an intention-to-treat analysis, the difference in the hazard-ratio slopes for the effect of menopausal hormones on the risk of breast cancer during the intervention and postintervention phases was not significant (P=0.28 for the difference in trend). In a sensitivity analysis that repeated these analyses with an adjustment for adherence, a significant difference in the hazard ratio slopes was detected (P=0.005 for the difference in trend) (Figure 1). The adherence-adjusted hazard ratio during the intervention was 1.62 (95% CI, 1.10 to 2.39) as compared with a hazard ratio after the intervention of 1.26 (95% CI, 0.73 to 2.20).The annualized incidence of breast cancer was greater in the hormone-therapy group than in the placebo group during the later years of the intervention phase, but the number of breast-cancer diagnoses in the hormone-therapy group decreased by 28% from the last year of the intervention phase to the first year of the postintervention phase (from 48 cases [0.61%] to 34 cases [0.44%]) (Table 2Table 2
Year-to-Year Breast-Cancer Incidence and Means of Detection before and after Intervention Ended, According to Study Group.). Mammography use was similar in the hormone-therapy and placebo groups throughout the trial, including the years immediately before and after the intervention ended (Table 2).Breast tumors diagnosed in the hormone-therapy group during the postintervention phase were significantly larger than those in the placebo group (mean [±SD] diameter, 1.5±1.2 cm vs. 1.1±0.8 cm; P=0.03), but other tumor characteristics, including the stage, were similar. During the postintervention phase, mammograms with abnormalities were more common in the hormone-therapy group than in the placebo group (cumulative number, 780 [7.5%] vs. 589 [5.4%]; P<0.001), and breast biopsies were more frequent (cumulative number, 538 [2.3%] vs. 319 [1.4%]; P<0.001).
Observational Study
Participants in the observational study who were taking estrogen plus progestin at study entry, as compared with those who were not, were more likely to be white, younger, more highly educated, and nonsmokers; they were also more likely to have a lower body-mass index, to consume more alcohol, to engage in more physical activity, and to have better self-reported health, no family history of breast cancer, and a lower Gail-model estimate of breast-cancer risk (P<0.001 for all comparisons) (data not shown). The mean duration of hormone therapy in the group of women taking hormones at entry was 6.9±5.4 years.
Figure 2Figure 2
Effects over Time of Estrogen plus Progestin on the Risk of Breast Cancer in the WHI Observational Study. shows a smoothed, multivariable-adjusted, nonparametric estimate of the hazard ratios over time for women taking estrogen plus progestin, which summarizes the sequential, semiannual, multivariable-adjusted hazard ratios. Before 2002, the smoothed estimate of the hazard ratio was nearly 2.00. Between 2002 and the 2004, the hazard ratio decreased significantly (P=0.004 for trend, for the difference in slope in the two intervals), ultimately reaching a value that did not differ significantly from 1.00.The incidence of breast cancer among the women taking hormones was relatively stable for the years 2000 through 2002 and was consistently greater than that among women not taking hormones (Table 3Table 3
Year-to-Year Breast-Cancer Incidence and Means of Detection in the Observational Study According to Whether the Participants Were Using Hormone Therapy.). Paralleling the year-to-year decrease in hormone use, which began in 2001 and accelerated in 2003 (Figure 2), a lower annualized incidence of breast cancer began to emerge in the group of women taking hormones (Table 3), with a 43% reduction in the annualized incidence of breast cancer from 2002 to 2003 (122 cases [0.81%] vs. 68 cases [0.46%]). The annual frequency of mammography was lower in the group of women who were not taking hormones than in the group of women who were taking hormones, and this pattern was consistent over time (P<0.01).In a sensitivity analysis for adherence, which was adjusted for changes in hormone use after study entry and in which linear time-varying hazard-ratio models were used for the intervals before and after July 2002, corresponding to the announcement of trial results, we observed a decreasing trend in the hazard ratio in the hormone-therapy group (Figure 3Figure 3
Adherence-Adjusted Effects over Time of Estrogen plus Progestin on the Risk of Breast Cancer in the WHI Observational Study.) (P=0.01 for trend, for the difference in slope in the two intervals).Discussion
Analysis of two WHI cohorts — the cohort in the WHI randomized trial comparing menopausal hormone use with placebo and the cohort in the WHI observational study — yielded a composite picture of the influence of estrogen plus progestin on the incidence of breast cancer and breast-cancer detection during the period when women were taking menopausal hormones as well as after they stopped taking them. In the clinical trial, the number of breast-cancer diagnoses in the hormone-therapy group was initially lower than that in the placebo group, perhaps reflecting the interference of hormonal effects on breast tissue with the interpretation of mammographic findings.3 The incidence increased as the duration of exposure increased and subsequently decreased in the postintervention period. In the observational study, the incidence of breast cancer was initially about twice as high among women who used hormones as among those who did not use them, a finding that probably reflected the longer duration of hormone exposure in this study than in the clinical trial.22,23 Nonetheless, the incidence decreased in parallel with the year-to-year reduction in the use of estrogen plus progestin. The rapid decrease in breast cancers during the postintervention period suggests that withdrawal of estrogen-plus-progestin therapy leads to a regression of preclinical cancers. 7
Most participants stopped taking the study pills when instructed to do so on July 8, 2002, and 1 year later, only 4% of participants reported using hormone therapy that was unrelated to the study.24 In the observational study, hormone use in the group of women who reported its use at study entry began to decrease in 2001, perhaps reflecting concerns about safety in view of the results of the Heart and Estrogen/Progestin Replacement Study (HERS).25 The decline in the use of combined hormones subsequently accelerated, with a 50% decrease in 2003 as compared with 2000. The magnitude of this decrease reflects secular population trends,4 but the decrease began somewhat earlier in the observational study than in the general population, perhaps because the study participants were more aware of the HERS results.
A population-based change in the incidence of breast cancer might be attributable to factors other than discontinuation of hormone therapy. Such factors include the initial prevalence of hormone-therapy use, hormone prescribing practices (areas with relatively low use are likely to prescribe hormones mainly for women at low risk for breast cancer), the change in hormone-therapy use over the period of observation, the validity of the assessment of hormone-therapy use, the frequency of mammography, change in frequency of mammography use over the period of observation, and the validity of the estimate of mammography use.26
The decrease in breast-cancer incidence rates in the hormone-therapy groups in both the WHI clinical trial and the observational study after July 2002 cannot, however, be explained by differences in use of mammography. In the postintervention phase of the clinical trial, annual rates of mammography remained nearly identical in the hormone-therapy and placebo groups, whereas the incidence of breast cancer in the hormone-therapy group declined substantially. In the observational study, the difference in frequency of mammography use of 2% between 2002 and 2003 for women using hormones is insufficient to account for the 43% reduction in the incidence of breast cancer. In addition, the difference in frequency of mammography use between women who did and those who did not use hormones was constant over the entire interval, whereas the hazard ratio for breast cancer in the hormone-therapy group changed markedly. These findings suggest that the carryover effect of combined hormone therapy on the risk of breast cancer is time-limited and is not explained by changes in frequency of mammography use.
After the initial report of a decrease in the incidence of breast cancer beginning in 2003,6,7 subsequent reports have largely supported a relation between the use of menopausal hormone-replacement therapy and breast-cancer rates,8-10,27 but discordant results11,12 and controversy regarding causality13,14 remain. Prior analyses did not control for risk factors, frequency of mammography, or dose, schedule, and type of menopausal hormone replacement. Kerlikowske and colleagues reported a similar change in the incidence of breast cancer in a population followed after screening mammography,28 and a California report correlated county-by-county changes in hormone therapy with changes in the incidence of breast cancer.27 In the two WHI populations, detailed information regarding risk factors for breast cancer was collected at study entry, menopausal hormone-therapy use at entry was carefully assessed by means of a questionnaire administered by trained interviewers, data on frequency of mammography and findings were collected prospectively, and breast cancer was verified by central adjudication. In addition, the precise stopping date for menopausal hormone use is known in the clinical trial, and information on continuing hormone use was obtained annually in the observational study. The influence of these factors on the incidence of breast cancer was controlled by randomization in the clinical trial and by multivariate regression models in the observational study. Additional strengths of the current analysis include the randomized design of the clinical trial and the complementary nature of the independent findings in the well-characterized observational-study cohort.
The recent update of the Surveillance, Epidemiology, and End Results (SEER) Program shows that the reduction in the incidence of breast cancer among postmenopausal women in the United States that was initially observed in 2002 has been sustained through 2005 and that the reduction has occurred among women 50 to 69 years of age but not among older or younger women.29 Given breast-tumor doubling times of about 150 days,30-32 the absence of so-called catch-up incidence argues against the idea that differences in mammography practices can explain the decline in the incidence of breast cancer.
There is controversy regarding mammography use in the United States. A comparison of use between 2000 and 2005 suggested a decrease in annual mammography of about 5%,33 perhaps mainly among women between 40 and 59 years of age.34 However, a recent analysis of Medicare claims showed a 5% increase in mammography use over the same period for participants in Medicare fee-for-service plans.35
In summary, the increased risk of breast cancer associated with estrogen-plus-progestin therapy declined markedly soon after discontinuation of the therapy and was unrelated to a change in the use of mammography. This finding supports the hypothesis that the recent reduction in the incidence of breast cancer among women in certain age groups in the United States is predominantly related to a decrease in the use of combined estrogen plus progestin.
Supported by grants from the National Heart, Lung, and Blood Institute (N01WH22110, N01WH24152, N01WH32100-2, N01WH32105-6, N01WH32108-9, N01WH32111-13, N01WH32115, N01WH32118-32119, N01WH32122, N01WH42107-26, N01WH42129-32, and N01WH44221).
Dr. Chlebowski reports receiving consulting fees from AstraZeneca, Novartis, Pfizer, Eli Lilly, and Wyeth Pharmaceuticals, lecture fees from AstraZeneca, Novartis, and Abraxis, and grant support from Amgen, Eli Lilly, and Organon. Dr. Gass reports receiving consulting fees from Upsher-Smith Laboratories, Wyeth Pharmaceuticals, and Procter & Gamble and funding for multisite clinical trials from Procter & Gamble and Wyeth Pharmaceuticals. Dr. Rohan reports receiving consulting fees from legal firms regarding hormone-therapy issues. Dr. Hendrix reports receiving consulting fees from Meditrina Pharmaceuticals, lecture fees from Merck, and grant support from Boehringer Ingelheim and Organon. No other potential conflict of interest relevant to this article was reported.
Source Information
From the Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center, Torrance, CA (R.T.C.); the University of Pittsburgh, Pittsburgh (L.H.K.); the Fred Hutchinson Cancer Research Center, Seattle (R.L.P., A.K.A., G.A.); the Stanford Prevention Research Center, Stanford, CA (M.L.S.); Brigham and Women's Hospital and Harvard Medical School, Boston (J.E.M.); the University of Cincinnati, Cincinnati (M.G.); the University of Massachusetts, Fallon Clinic, Worcester (J.K.O.); the State University of New York at Stony Brook, Stony Brook (D.S.L.); the University of Wisconsin, Madison (G.E.S.); Baylor College of Medicine, Houston (A.R.); the University of Texas Health Science Center at San Antonio, San Antonio (R.S.); Wayne State University School of Medicine and Hutzel Hospital, Detroit (S.L.H.); the University of Texas M.D. Anderson Cancer Center, Houston (P.M.R.); the Albert Einstein College of Medicine, Bronx, NY (T.E.R.); and the University of California at Davis, Sacramento (S.Y.).
Address reprint requests to Dr. Chlebowski at the Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center, 1124 W. Carson St., Torrance, CA 90502, or at rchlebowski@gmail.com.
A complete list of the Women's Health Initiative (WHI) investigators appears in the Appendix.
Appendix
The following investigators participated in the Women's Health Initiative studies: Program Office: National Heart, Lung, and Blood Institute, Bethesda, MD — E. Nabel, J. Rossouw, S. Ludlam, J. McGowan, N. Geller, L. Ford. Clinical Coordinating Center: Fred Hutchinson Cancer Research Center, Seattle — R. Prentice, G.L. Anderson, A. LaCroix, R. Patterson, A. McTiernan, B. Cochrane, J. Hunt, L. Tinker, C. Kooperberg, M. McIntosh, C.Y. Wang, C. Chen, D. Bowen, A. Kristal, J. Stanford, N. Urban, N. Weiss, E. White; Medical Research Laboratories, Highland Heights, KY — E. Stein, P. Laskarzewski; San Francisco Coordinating Center, San Francisco — S.R. Cummings, M. Nevitt, L. Palermo; University of Minnesota, Minneapolis — L. Harnack; Fisher BioServices, Rockville, MD — F. Cammarata, S. Lindenfelser; University of Washington, Seattle — B. Psaty, S. Heckbert. Clinical Centers: Albert Einstein College of Medicine, Bronx, NY — S. Wassertheil-Smoller, W. Frishman, J. Wylie-Rosett, D. Barad, R. Freeman; Baylor College of Medicine, Houston — A. Rajkovic, J. Hays, R. Young, H. Sangi-Haghpeykar; Brigham and Women's Hospital, Harvard Medical School, Boston — J.E. Manson, K.M. Rexrode, B. Walsh, J.M. Gaziano, M. Bueche; Brown University, Providence, RI — C.B. Eaton, M. Cyr, G. Sloane; Emory University, Atlanta — L. Phillips, V. Butler, V. Porter; Fred Hutchinson Cancer Research Center, Seattle — S.A.A. Beresford, V.M. Taylor, N.F. Woods, M. Henderson, R. Andersen; George Washington University, Washington, DC — L. Martin, J. Hsia, N. Gaba, R. Katz; Los Angeles Biomedical Research Institute at Harbor–UCLA Research and Education Institute, Torrance, CA — R. Chlebowski, R. Detrano, A. Nelson, M. Geller; Kaiser Permanente Center for Health Research, Portland, OR — Y. Michael, E. Whitlock, V. Stevens, N. Karanja; Kaiser Permanente Division of Research, Oakland, CA — B. Caan, S. Sidney, G.B.J. Hirata; Medical College of Wisconsin, Milwaukee — J. Morley Kotchen, V. Barnabei, T.A. Kotchen, M.A.C. Gilligan, J. Neuner; MedStar Research Institute–Howard University, Washington, DC — B.V. Howard, L. Adams-Campbell, L. Lessin, C. Iglesia, L.K. Mickel; Northwestern University, Chicago–Evanston — L. Van Horn, P. Greenland, J. Khandekar, K. Liu, C. Rosenberg; Rush University Medical Center, Chicago — H. Black, L. Powell, E. Mason, M. Gulati; Stanford Prevention Research Center, Stanford, CA — M.L. Stefanick, M.A. Hlatky, B. Chen, R.S. Stafford, S. Mackey; State University of New York at Stony Brook, Stony Brook — D. Lane, I. Granek, W. Lawson, C. Messina, G. San Roman; Ohio State University, Columbus — R. Jackson, R. Harris, E. Paskett, W.J. Mysiw, M. Blumenfeld; University of Alabama at Birmingham, Birmingham — C.E. Lewis, A. Oberman, J.M. Shikany, M. Safford; University of Arizona, Tucson–Phoenix — C.A. Thomson, T. Bassford, C. Ritenbaugh, Z. Chen, M. Ko; University at Buffalo, Buffalo, NY — J. Wactawski-Wende, M. Trevisan, E. Smit, S. Graham, J. Chang; University of California at Davis, Sacramento — J. Robbins, S. Yasmeen; University of California at Irvine, Irvine — F.A. Hubbell, G. Frank, N. Wong, N. Greep, B. Monk; University of California at Los Angeles, Los Angeles — L. Nathan, D. Heber, R. Elashoff, S. Liu; University of California at San Diego, La Jolla–Chula Vista — R.D. Langer, M.H. Criqui, G.T. Talavera, C.F. Garland, M.A. Allison; University of Cincinnati, Cincinnati — M. Gass, N. Watts; University of Florida, Gainesville–Jacksonville — M. Limacher, M. Perri, A. Kaunitz, R.S. Williams, Y. Brinson; University of Hawaii, Honolulu — J.D. Curb, H. Petrovitch, B. Rodriguez, K. Masaki, P. Blanchette; University of Iowa, Iowa City–Davenport — R. Wallace, J. Torner, S. Johnson, L. Snetselaar, J. Robinson; University of Massachusetts, Fallon Clinic, Worcester — J. Ockene, M. Rosal, I. Ockene, R. Yood, P. Aronson; University of Medicine and Dentistry of New Jersey, Newark — N. Lasser, B. Singh, V. Lasser, J. Kostis, P. McGovern; University of Miami, Miami — M.J. O'Sullivan, L. Parker, J. Potter, D. Fernandez, P. Caralis; University of Minnesota, Minneapolis — K.L. Margolis, R.H. Grimm, M.F. Perron, C. Bjerk, S. Kempainen; University of Nevada, Reno — R. Brunner, W. Graettinger, V. Oujevolk, M. Bloch; University of North Carolina, Chapel Hill — G. Heiss, P. Haines, D. Ontjes, C. Sueta, E. Wells; University of Pittsburgh, Pittsburgh — L. Kuller, J. Cauley, N.C. Milas; University of Tennessee Health Science Center, Memphis — K.C. Johnson, S. Satterfield, R. Li, S. Connelly, F. Tylavsky; University of Texas Health Science Center, San Antonio — R. Brzyski, R. Schenken; University of Wisconsin, Madison — G.E. Sarto, D. Laube, P. McBride, J. Mares, B. Loevinger; Wake Forest University School of Medicine, Winston-Salem, NC — M. Vitolins, G. Burke, R. Crouse, S. Washburn; Wayne State University School of Medicine–Hutzel Hospital, Detroit — M. Simon. Women's Health Initiative Memory Study: Wake Forest University School of Medicine, Winston-Salem, NC — S. Shumaker, S. Rapp, C. Legault, M. Espeland, L. Coker. Former Principal Investigators and Project Officers: Baylor College of Medicine, Houston — J. Hays, J. Foreyt; Brown University, Providence, RI — A.R. Assaf; Emory University, Atlanta — D. Hall; George Washington University, Washington, DC — V. Miller; Kaiser Permanente Center for Health Research, Portland, OR — B. Valanis; Kaiser Permanente Division of Research, Oakland, CA — R. Hiatt; National Cancer Institute, Bethesda, MD — C. Clifford (deceased); National Heart, Lung, and Blood Institute, Bethesda, MD — L. Pottern; University of California at Irvine, Irvine — F. Meyskens, Jr.; University of California at Los Angeles, Los Angeles — H. Judd (deceased); University of Cincinnati, Cincinnati — J. Liu, N. Watts; University of Miami, Miami — M. Baum; University of Minnesota, Minneapolis — R. Grimm; University of Nevada, Reno — S. Daugherty; University of North Carolina, Chapel Hill — D. Sheps, B. Hulka; University of Tennessee Health Science Center, Memphis — W. Applegate; University of Wisconsin, Madison — C. Allen (deceased); Wake Forest University School of Medicine, Winston-Salem, NC — D. Bonds.
- References
References
1
Rossouw JE ,Anderson GL ,Prentice RL , et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
CrossRef | Web of Science | Medline2
Chlebowski RT ,Hendrix SL ,Langer RD , et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243-3253
CrossRef | Web of Science | Medline3
Chlebowski RT ,Anderson GL ,Pettinger M , et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med 2008;168:370-377
CrossRef | Web of Science | Medline4
Hersh AL ,Stefanick ML ,Stafford RS . National use of menopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53
CrossRef | Web of Science | Medline5
Haas JS ,Kaplan CP ,Gerstenberger EP ,Kerlikowske K . Changes in the use of postmenopausal hormone therapy with the publication of clinical trial results. Ann Intern Med 2004;140:184-188
Web of Science | Medline6
Clarke CA ,Glaser SL ,Uratsu CS ,Selby JV ,Kushi LH ,Herrinton LJ . Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006;24:e49-e50
CrossRef | Medline7
Ravdin PM ,Cronin K ,Howlander N , et al. A sharp decrease in breast cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-1674
Full Text | Web of Science | Medline8
Katalinic A ,Rawal R . Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008;107:427-430
CrossRef | Web of Science | Medline9
Canfell K ,Banks E ,Moa AM ,Beral V . Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 2008;188:641-644
Web of Science | Medline10
Allemand H ,Seradour B ,Weill A ,Ricordeau P . Decline in breast cancer incidence in 2005 and 2006 in France: a paradoxical trend. Bull Cancer (Paris) 2008;95:11-15
Web of Science | Medline11
Zahl PH ,Maehlen J . A decline in breast cancer incidence. N Engl J Med 2007;357:510-511
Web of Science | Medline12
Vaidya JS . Declines in invasive breast cancer and use of menopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2008;100:598-599
CrossRef | Web of Science | Medline13
Jemal A ,Ward E ,Thun MJ . Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007;9:R28-R28
CrossRef | Web of Science | Medline14
MacMahon B ,Cole P . Is the breast cancer incidence declining? Epidemiology 2008;19:268-269
CrossRef | Web of Science | Medline15
Heiss G ,Wallace R ,Anderson GL , et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-1045
CrossRef | Web of Science | Medline16
The Women's Health Initiative Study Group
CrossRef | Medline17
Hays J ,Hunt JR ,Hubbel FA , et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol 2003;13:Suppl:S18-S77
CrossRef | Web of Science | Medline18
Manson JE ,Hsia J ,Johnson KC , et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534
Full Text | Web of Science | Medline19
Yasmeen S ,Romano PS ,Pettinger M , et al. Frequency and predictive value of a mammographic recommendation for short-interval follow-up. J Natl Cancer Inst 2003;95:429-436
CrossRef | Web of Science | Medline20
Grambsch P ,Therneau T . Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-526
CrossRef | Web of Science21
Gail MH ,Brinton LA ,Byar DP , et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1886
CrossRef | Web of Science | Medline22
Prentice RL ,Chlebowski RT ,Stefanick ML , et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2008;167:1207-1216
CrossRef | Web of Science | Medline23
Beral V . Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427[Erratum, Lancet 2003;362:1160.]
CrossRef | Web of Science | Medline24
Ockene JK ,Barad DH ,Cochrane BB , et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005;294:183-193
CrossRef | Web of Science | Medline25
Hulley S ,Grady B ,Bush T , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613
CrossRef | Web of Science | Medline26
Ravdin PM ,Cronin KA ,Chlebowski RT . A decline in breast-cancer incidence. N Engl J Med 2007;357:513-513
Web of Science27
Robbins AS ,Clarke CA . Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 2007;25:3437-3439
CrossRef | Web of Science | Medline28
Kerlikowske K ,Miglioretti DL ,Buist DS ,Walker R ,Carney PA . Declines in invasive breast cancer and use of menopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2007;99:1335-1339[Erratum, J Natl Cancer Inst 2007;99:1493.]
CrossRef | Web of Science | Medline29
Surveillance, Epidemiology and End Results Program home page. (Accessed January 12, 2009, at http://seer.cancer.gov/.)
30
Kuroishi T ,Tominaga S ,Morimoto T , et al. Tumor growth rate and prognosis of breast cancer mainly detected by mass screening. Jpn J Cancer Res 1990;81:454-462
CrossRef | Medline31
Tilanus-Linthorst MM ,Kriege M ,Boetes C , et al. Hereditary breast cancer growth rates and its impact on screening policy. Eur J Cancer 2005;41:1610-1617
CrossRef | Web of Science | Medline32
Peer PG ,van Djick JA ,Hendriks JH ,Holland R ,Verbeek AL . Age-dependent growth of primary breast cancer. Cancer 1993;71:3547-3551
CrossRef | Web of Science | Medline33
Health, United States 2006, with chartbook on trends in health of Americans. Table 84. Hyattsville, MD: National Center for Health Statistics, 2006. (DHHS publication no. 2006-1232.)
34
Ryerson AB ,Miller JW ,Eheman CR ,Leadbetter S ,White MC . Recent trends in U.S. mammography use from 2000-2006: a population-based analysis. Prev Med 2008;47:477-482
CrossRef | Web of Science | Medline35
Rao VM ,Levin DC ,Parker L ,Frangos AJ . Recent trends in mammography utilization in the Medicare population: is there a cause for concern? J Am Coll Radiol 2008;5:652-656
CrossRef | Medline
- Citing Articles (83)
Citing Articles
1
R. Hein, S. Abbas, P. Seibold, R. Salazar, D. Flesch-Janys, J. Chang-Claude. (2012) Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy. Breast Cancer Research and Treatment 131:2, 653-661
CrossRef2
Christina Justenhoven, Ofure Obazee, Stefan Winter, Fergus J. Couch, Janet E. Olson, Per Hall, Ulf Hannelius, Jingmei Li, Keith Humphreys, Gianluca Severi, Graham Giles, Melissa Southey, Laura Baglietto, Peter A. Fasching, Matthias W. Beckmann, Arif B. Ekici, Ute Hamann, Christian Baisch, Volker Harth, Sylvia Rabstein, Anne Lotz, Beate Pesch, Thomas Brüning, Yon-Dschun Ko, Hiltrud Brauch. (2012) The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant. Breast Cancer Research and Treatment 131:1, 347-350
CrossRef3
Peter Greaves. 2012. Mammary Gland. , 69-97.
CrossRef4
Emiel Rutgers, Martine J. Piccart-Gebhart, Jan Bogaerts, Suzette Delaloge, Laura Van ‘t Veer, Isabel Teresa Rubio, Giuseppe Viale, Alastair M. Thompson, Rodolfo Passalacqua, Ulrike Nitz, Anita Vindevoghel, Jean-Yves Pierga, Peter M. Ravdin, Gustavo Werutsky, Fatima Cardoso. (2011) The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase. European Journal of Cancer 47:18, 2742-2749
CrossRef5
J. A. A. M. van Dijck, J. D. M. Otten, N. Karssemeijer, P. Kenemans, A. L. M. Verbeek, M. J. van der Mooren. (2011) Less mammographic density after nasal versus oral administration of postmenopausal hormone therapy. Climacteric 14:6, 683-688
CrossRef6
J. C. Stevenson, H. N. Hodis, J. H. Pickar, R. A. Lobo. (2011) HRT and breast cancer risk: a realistic perspective. Climacteric 14:6, 633-636
CrossRef7
V. S. Blinder, M. M. Murphy, L. T. Vahdat, H. T. Gold, I. Melo-Martin, M. K. Hayes, R. J. Scheff, E. Chuang, A. Moore, M. Mazumdar. (2011) Employment After a Breast Cancer Diagnosis: A Qualitative Study of Ethnically Diverse Urban Women. Journal of Community Health
CrossRef8
J. Collins. (2011) Editor's reply: Hormonal contraception and risk of cancer. Human Reproduction Update 17:6, 861-862
CrossRef9
Judith M. E. Walsh, Megan McNamara, Redonda G. Miller, Eleanor Bimla Schwarz. (2011) Update in Women’s Health for the General Internist. Journal of General Internal Medicine
CrossRef10
Farzana Choudhury, Leslie Bernstein, Howard N. Hodis, Frank Z. Stanczyk, Wendy J. Mack. (2011) Physical activity and sex hormone levels in estradiol- and placebo-treated postmenopausal women. Menopause 18:10, 1079-1086
CrossRef11
(2011) Exemestane for Breast-Cancer Prevention. New England Journal of Medicine 365:11, 1056-1058
Full Text12
Mary Panjari, Susan R. Davis. (2011) Vaginal DHEA to treat menopause related atrophy: A review of the evidence. Maturitas 70:1, 22-25
CrossRef13
Nicole L. Moore, Theresa E. Hickey, Lisa M. Butler, Wayne D. Tilley. (2011) Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells. Molecular and Cellular Endocrinology
CrossRef14
Chia-Hwa Lee, Ya-Chieh Chang, Ching-Shyang Chen, Shih-Hsin Tu, Ying-Jan Wang, Li-Ching Chen, Yu-Jia Chang, Po-Li Wei, Hui-Wen Chang, Chien-Hsi Chang, Ching-Shui Huang, Chih-Hsiung Wu, Yuan-Soon Ho. (2011) Crosstalk between nicotine and estrogen-induced estrogen receptor activation induces α9-nicotinic acetylcholine receptor expression in human breast cancer cells. Breast Cancer Research and Treatment 129:2, 331-345
CrossRef15
Wendy Y. Chen. (2011) Postmenopausal Hormone Therapy and Breast Cancer Risk: Current Status and Unanswered Questions. Endocrinology & Metabolism Clinics of North America 40:3, 509-518
CrossRef16
Christy R. Hagan, Andrea R. Daniel, Gwen E. Dressing, Carol A. Lange. (2011) Role of phosphorylation in progesterone receptor signaling and specificity. Molecular and Cellular Endocrinology
CrossRef17
R. L. Prentice. (2011) Empirical Evaluation of Gene and Environment Interactions: Methods and Potential. JNCI Journal of the National Cancer Institute 103:16, 1209-1210
CrossRef18
J. J. Fenton, L. Abraham, S. H. Taplin, B. M. Geller, P. A. Carney, C. D'Orsi, J. G. Elmore, W. E. Barlow, . (2011) Effectiveness of Computer-Aided Detection in Community Mammography Practice. JNCI Journal of the National Cancer Institute 103:15, 1152-1161
CrossRef19
Steven A. Narod. (2011) Hormone replacement therapy and the risk of breast cancer. Nature Reviews Clinical Oncology 8:11, 669-676
CrossRef20
M. Nielsen, G. Karemore, M. Loog, J. Raundahl, N. Karssemeijer, J.D.M. Otten, M.A. Karsdal, C.M. Vachon, C. Christiansen. (2011) A novel and automatic mammographic texture resemblance marker is an independent risk factor for breast cancer. Cancer Epidemiology 35:4, 381-387
CrossRef21
E. Kohl, J. Steinbauer, M. Landthaler, R.-M. Szeimies. (2011) Skin ageing. Journal of the European Academy of Dermatology and Venereology 25:8, 873-884
CrossRef22
C. Antoine, L. Ameye, M. Moreau, M. Paesmans, S. Rozenberg. (2011) Evolution of breast cancer incidence in relation to hormone replacement therapy use in Belgium. Climacteric 14:4, 464-471
CrossRef23
Judy King, Catherine Harper Wynne, Laura Assersohn, Alison Jones. (2011) Hormone replacement therapy and women with premature menopause – A cancer survivorship issue. European Journal of Cancer 47:11, 1623-1632
CrossRef24
M. Levis. (2011) FLT3/ITD AML and the law of unintended consequences. Blood 117:26, 6987-6990
CrossRef25
Dieter Hölzel, Rebecca T. Emeny, Jutta Engel. (2011) True local recurrences do not metastasize. Cancer and Metastasis Reviews 30:2, 161-176
CrossRef26
Jo Anne Zujewski, Linda C. Harlan, Donna M. Morrell, Jennifer L. Stevens. (2011) Ductal carcinoma in situ: trends in treatment over time in the US. Breast Cancer Research and Treatment 127:1, 251-257
CrossRef27
Usha Salagame, Karen Canfell, Emily Banks. (2011) An epidemiological overview of the relationship between hormone replacement therapy and breast cancer. Expert Review of Endocrinology & Metabolism 6:3, 397-409
CrossRef28
Sandra A. Tsai, Marcia L. Stefanick, Randall S. Stafford. (2011) Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause 18:4, 385-392
CrossRef29
Debjani Grenier, Andrew L. Cooke, Lisa Lix, Colleen Metge, Huimin Lu, William D. Leslie. (2011) Bone mineral density and risk of postmenopausal breast cancer. Breast Cancer Research and Treatment 126:3, 679-686
CrossRef30
Sharon Bond. (2011) NEW FINDINGS FROM WOMEN'S HEALTH INITIATIVE: BREAST CANCER MORTALITY RATES HIGHER AMONG COMBINATION HORMONE THERAPY USERS. Journal of Midwifery & Women's Health 56:2, 177-178
CrossRef31
Alfred O. Mueck, Xiangyan Ruan. (2011) Benefits and risks during HRT: main safety issue breast cancer. Hormone Molecular Biology and Clinical Investigation 5:2, 105-116
CrossRef32
Paolo Boffetta, Graham A. Colditz, John D. Potter, Laurence Kolonel, Paula J. Robson, Reza Malekzadeh, Daniela Seminara, Ellen L. Goode, Keun-Young Yoo, Paul Demers, Richard Gallagher, Ross Prentice, Yutaka Yasui, Kieran O’Doherty, Gloria M. Petersen, Cornelia M. Ulrich, Ilona Csizmadi, Ernest K. Amankwah, Nigel T. Brockton, Karen Kopciuk, S. Elizabeth McGregor, Linda E. Kelemen. (2011) Cohorts and consortia conference: a summary report (Banff, Canada, June 17–19, 2009). Cancer Causes & Control 22:3, 463-468
CrossRef33
Nancy Krieger, Jarvis T. Chen, Pamela D. Waterman. (2011) Temporal trends in the black/white breast cancer case ratio for estrogen receptor status: disparities are historically contingent, not innate. Cancer Causes & Control 22:3, 511-514
CrossRef34
R. T. Chlebowski, G. L. Anderson. (2011) The Influence of Time From Menopause and Mammography on Hormone Therapy-Related Breast Cancer Risk Assessment. JNCI Journal of the National Cancer Institute 103:4, 284-285
CrossRef35
L. Daubisse-Marliac, P. Delafosse, J. B. Boitard, F. Poncet, P. Grosclaude, M. Colonna. (2011) Breast cancer incidence and time trend in France from 1990 to 2007: a population-based study from two French cancer registries. Annals of Oncology 22:2, 329-334
CrossRef36
Neal A. Englert, Barbara C. Spink, David C. Spink. (2011) Persistent and non-persistent changes in gene expression result from long-term estrogen exposure of MCF-7 breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology 123:3-5, 140-150
CrossRef37
Mais M Al-Mumen, Asad A Al-Janabi, Alaa S Jumaa, Kaswer M Al-Toriahi, Akeel A Yasseen. (2011) Exposure to depleted uranium does not alter the co-expression of HER-2/neu and p53 in breast cancer patients. BMC Research Notes 4:1, 87
CrossRef38
Kjersti Bakken, Agnès Fournier, Eiliv Lund, Marit Waaseth, Vanessa Dumeaux, Françoise Clavel-Chapelon, Alban Fabre, Bertrand Hémon, Sabina Rinaldi, Véronique Chajes, Nadia Slimani, Naomi E. Allen, Gillian K. Reeves, Sheila Bingham, Kay-Tee Khaw, Anja Olsen, Anne Tjønneland, Laudina Rodriguez, Maria-José Sánchez, Pilar Amiano Etxezarreta, Eva Ardanaz, Maria-José Tormo, Petra H. Peeters, Carla H. van Gils, Annika Steffen, Mandy Schulz, Jenny Chang-Claude, Rudolf Kaaks, Rosario Tumino, Valentina Gallo, Teresa Norat, Elio Riboli, Salvatore Panico, Giovanna Masala, Carlos A. González, Franco Berrino. (2011) Menopausal hormone therapy and breast cancer risk: Impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer 128:1, 144-156
CrossRef39
Claudia Aguirre, Anusha Jayaraman, Christian Pike, Michel Baudry. (2010) Progesterone inhibits estrogen-mediated neuroprotection against excitotoxicity by down-regulating estrogen receptor-β. Journal of Neurochemistry 115:5, 1277-1287
CrossRef40
Dieter Hölzel, Renate Eckel, Rebecca T. Emeny, Jutta Engel. (2010) Distant metastases do not metastasize. Cancer and Metastasis Reviews 29:4, 737-750
CrossRef41
Brian Cox, Rachel Ballard-Barbash, Mireille Broeders, Emily Dowling, Nea Malila, Rene Shumak, Stephen Taplin, Diana Buist, Diana Miglioretti. (2010) Recording of hormone therapy and breast density in breast screening programs: summary and recommendations of the International Cancer Screening Network. Breast Cancer Research and Treatment 124:3, 793-800
CrossRef42
Delfin Rodriguez-Leyva, Chantal M.C. Bassett, Richelle McCullough, Grant N. Pierce. (2010) The cardiovascular effects of flaxseed and its omega-3 fatty acid, alpha-linolenic acid. Canadian Journal of Cardiology 26:9, 489-496
CrossRef43
P. De, C. I. Neutel, I. Olivotto, H. Morrison. (2010) Breast Cancer Incidence and Hormone Replacement Therapy in Canada. JNCI Journal of the National Cancer Institute 102:19, 1489-1495
CrossRef44
F. Canzian, D. G. Cox, V. W. Setiawan, D. O. Stram, R. G. Ziegler, L. Dossus, L. Beckmann, H. Blanche, A. Barricarte, C. D. Berg, S. Bingham, J. Buring, S. S. Buys, E. E. Calle, S. J. Chanock, F. Clavel-Chapelon, J. O. L. DeLancey, W. R. Diver, M. Dorronsoro, C. A. Haiman, G. Hallmans, S. E. Hankinson, D. J. Hunter, A. Husing, C. Isaacs, K.-T. Khaw, L. N. Kolonel, P. Kraft, L. Le Marchand, E. Lund, K. Overvad, S. Panico, P. H. M. Peeters, M. Pollak, M. J. Thun, A. Tjonneland, D. Trichopoulos, R. Tumino, M. Yeager, R. N. Hoover, E. Riboli, G. Thomas, B. E. Henderson, R. Kaaks, H. S. Feigelson. (2010) Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Human Molecular Genetics 19:19, 3873-3884
CrossRef45
Miranda A Farage, Kenneth W Miller, William Ledger. (2010) Confronting the challenges of postmenopausal urogenital health. Aging Health 6:5, 611-626
CrossRef46
S. Hentschel, J. Heinz, S. Schmid-Höpfner, N. Obi, E. Vettorazzi, J. Chang-Claude, D. Flesch-Janys. (2010) The impact of menopausal hormone therapy on the incidence of different breast cancer types – Data from the Cancer Registry Hamburg 1991–2006. Cancer Epidemiology 34:5, 639-643
CrossRef47
R. T. Chlebowski, G. L. Anderson, J. E. Manson, A. G. Schwartz, H. Wakelee, M. Gass, R. J. Rodabough, K. C. Johnson, J. Wactawski-Wende, J. M. Kotchen, J. K. Ockene, M. J. O'Sullivan, F. A. Hubbell, J. W. Chien, C. Chen, M. L. Stefanick. (2010) Lung Cancer Among Postmenopausal Women Treated With Estrogen Alone in the Women's Health Initiative Randomized Trial. JNCI Journal of the National Cancer Institute 102:18, 1413-1421
CrossRef48
Jayashri Kulkarni, Caroline Gurvich, Stuart J. Lee, Heather Gilbert, Emmy Gavrilidis, Anthony de Castella, Michael Berk, Seetal Dodd, Paul B. Fitzgerald, Susan R. Davis. (2010) Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 35:8, 1142-1147
CrossRef49
Ling Xu. (2010) How to judge the association of postmenopausal hormone therapy and the risk of breast cancer. Frontiers of Medicine in China 4:3, 290-293
CrossRef50
JoAnn V. Pinkerton, Dale W. Stovall. (2010) Reproductive aging, menopause, and health outcomes. Annals of the New York Academy of Sciences 1204:1, 169-178
CrossRef51
Erin J. Aiello Bowles, Melissa L. Anderson, Susan D. Reed, Katherine M. Newton, E. Dawn Fitzgibbons, Deborah Seger, Diana S.M. Buist. (2010) Mammographic Breast Density and Tolerance for Short-Term Postmenopausal Hormone Therapy Suspension. Journal of Women's Health 19:8, 1467-1474
CrossRef52
Claudio Pelucchi, Fabio Levi, Carlo La Vecchia. (2010) The rise and fall in menopausal hormone therapy and breast cancer incidence. The Breast 19:3, 198-201
CrossRef53
Mats Lambe, Annette Wigertz, Marit Holmqvist, Jan Adolfsson, Carola Bardage, Tommy Fornander, Per Karlsson, Viveca Odlind, Ingemar Persson, Johan Ahlgren, Leif Bergkvist. (2010) Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years. Breast Cancer Research and Treatment 121:3, 679-683
CrossRef54
C. La Vecchia, C. Bosetti, F. Lucchini, P. Bertuccio, E. Negri, P. Boyle, F. Levi. (2010) Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Annals of Oncology 21:6, 1323-1360
CrossRef55
M. Pollan, M. J. Michelena, E. Ardanaz, A. Izquierdo, M. J. Sanchez-Perez, A. Torrella, . (2010) Breast cancer incidence in Spain before, during and after the implementation of screening programmes. Annals of Oncology 21:Supplement 3, iii97-iii102
CrossRef56
Christian R. Loehberg, Sebastian M. Jud, Lothar Haeberle, Katharina Heusinger, Gerhard Dilbat, Alexander Hein, Claudia Rauh, Peter Dall, Nadine Rix, Sabrina Heinrich, Stefan Buchholz, Benno Lex, Barbara Reichler, Boris Adamietz, Ruediger Schulz-Wendtland, Matthias W. Beckmann, Peter A. Fasching. (2010) Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial. Breast Cancer Research and Treatment 121:1, 101-110
CrossRef57
Nancy Krieger, Jarvis T. Chen, Pamela D. Waterman. (2010) Decline in US Breast Cancer Rates After the Women's Health Initiative: Socioeconomic and Racial/Ethnic Differentials. American Journal of Public Health 100:S1, S132-S139
CrossRef58
D. Noss, O. Ortmann. (2010) Hormontherapie in der Peri- und Postmenopause. Der Gynäkologe 43:4, 318-323
CrossRef59
D. Noss, O. Ortmann. (2010) Hormontherapie in der Peri- und Postmenopause und Malignomrisiko. Gynäkologische Endokrinologie 8:1, 13-16
CrossRef60
Lewis H Kuller. (2010) Cardiovascular disease is preventable among women. Expert Review of Cardiovascular Therapy 8:2, 175-187
CrossRef61
G. Emons. (2010) Sexualsteroide und ihre onkogene Potenz. Gynäkologische Endokrinologie 8:1, 7-12
CrossRef62
Geir Jacobsen. (2010) Brystkreft - høyere dødelighet etter substitusjonsbehandling. Tidsskrift for Den norske legeforening 130:24, 2444-2444
CrossRef63
Tracy Onega, Todd MacKenzie, Julia Weiss, Martha Goodrich, Linda Titus-Ernstoff. (2010) Screening mammography intervals among postmenopausal hormone therapy users and nonusers. Cancer Causes & Control 21:1, 147-152
CrossRef64
Mandira Ray, Blase N. Polite. (2010) Triple-Negative Breast Cancers. The Cancer Journal 16:1, 17-22
CrossRef65
Rowan T Chlebowski, Ann G Schwartz, Heather Wakelee, Garnet L Anderson. (2010) Lung cancer and hormone replacement therapy – Authors' reply. The Lancet 375:9709, 118-119
CrossRef66
Nathan J. Coombs, Kathleen A. Cronin, Richard J. Taylor, Andrew N. Freedman, John Boyages. (2010) The impact of changes in hormone therapy on breast cancer incidence in the US population. Cancer Causes & Control 21:1, 83-90
CrossRef67
Rowan T. Chlebowski. (2009) Menopausal Hormone Therapy, Hormone Receptor Status, and Lung Cancer in Women. Seminars in Oncology 36:6, 566-571
CrossRef68
M. Pollan, R. Pastor-Barriuso, E. Ardanaz, M. Arguelles, C. Martos, J. Galceran, M.-J. Sanchez-Perez, M.-D. Chirlaque, N. Larranaga, R. Martinez-Cobo, M.-C. Tobalina, E. Vidal, R. Marcos-Gragera, A. Mateos, I. Garau, M.-D. Rojas-Martin, R. Jimenez, A. Torrella-Ramos, J. Perucha, M.-E. Perez-de-Rada, S. Gonzalez, M.-J. Rabanaque, J. Borras, C. Navarro, E. Hernandez, A. Izquierdo, G. Lopez-Abente, C. Martinez. (2009) Recent Changes in Breast Cancer Incidence in Spain, 1980-2004. JNCI Journal of the National Cancer Institute 101:22, 1584-1591
CrossRef69
Leslie Bernstein. (2009) Exercise and breast cancer prevention. Current Oncology Reports 11:6, 490-496
CrossRef70
Karen W. Kwan, Rowan T. Chlebowski. (2009) Sexual Dysfunction and Aromatase Inhibitor Use in Survivors of Breast Cancer. Clinical Breast Cancer 9:4, 219-224
CrossRef71
D. Hölzel, G. Schubert-Fritschle, J. Engel. (2009) Ergebnisse der interdisziplinären onkologischen Versorgung. Der Onkologe 15:11, 1120-1133
CrossRef72
E. Kohl, M. Landthaler, R.-M. Szeimies. (2009) Hautalterung. Der Hautarzt 60:11, 917-934
CrossRef73
Karen Canfell, Emily Banks, Mark Clements, Yoon Jung Kang, Aye Moa, Bruce Armstrong, Valerie Beral. (2009) Sustained lower rates of HRT prescribing and breast cancer incidence in Australia since 2003. Breast Cancer Research and Treatment 117:3, 671-673
CrossRef74
Helena M. Verkooijen, Christine Bouchardy, Vincent Vinh-Hung, Elisabetta Rapiti, Mikael Hartman. (2009) The incidence of breast cancer and changes in the use of hormone replacement therapy: A review of the evidence. Maturitas 64:2, 80-85
CrossRef75
Jeffrey A. Tice, Karla Kerlikowske. (2009) Screening and Prevention of Breast Cancer in Primary Care. Primary Care: Clinics in Office Practice 36:3, 533-558
CrossRef76
A. Goldhirsch, J. N. Ingle, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, . (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Annals of Oncology 20:8, 1319-1329
CrossRef77
R. Sutherland. (2009) Basic science: (February 2009). Breast Cancer Online 12:08,
CrossRef78
JoAnn V Pinkerton, Dale W Stovall, Rebecca S Kightlinger. (2009) Advances in the treatment of menopausal symptoms. Women's Health 5:4, 361-384
CrossRef79
Julianna Vig. (2009) Hormone therapy and breast cancer. Nature Reviews Endocrinology 5:6, 293-293
CrossRef80
J. Gligorov, D. Azria, Y. Belkacemi, M. Spielmann, M. Namer. (2009) La recherche clinique dans le domaine du cancer du sein: état des lieux et perspectives. Oncologie 11:6, 319-324
CrossRef81
(2009) Breast Cancer and Hormonal Therapy in Postmenopausal Women. New England Journal of Medicine 360:22, 2366-2367
Full Text82
Jacyntha A. Sterling. (2009) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 44:4, 354-359
CrossRef83
Serge Ferrari, Ego Seeman, Hong-Wen Deng, David G Little, Toshio Matsumoto. (2009) Clinical and basic research papers – March 2009. IBMS BoneKEy 6:3, 94-98
CrossRef
- Letters
